deCODE Genetics Announces Full-year 2007 Financi...(At December 31 At December 31 ...)

2007 2006

in thousands (unaudited)

Cash and investments* $94,058 $152,016

Total

assets 156,208 215,609

Total

liabilities 301,858 270,988

Total shareholders'

equity (145,650) (55,379)

* cash and investments include cash equivalents, restricted cash

equivalents and current and non-current investments

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, uncertainty regarding potential future deterioration in the market for auction rate securities which could result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, in
'/>"/>